L. Gambone

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

B. Gersh, S. Pocock, G. Stone, 2009, The Lancet.

Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.

A. Brickman, A. Baumbach, A. Lansky, 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).

A. Lansky, S. Carlier, U. Kaul, 2007, Indian heart journal.

Development and Validation of an Automated Algorithm for Endpoint Adjudication for a Large U.S. National Registry: Short Title: Automated Adjudication Algorithm.

A. Farb, J. Curtis, Yongfei Wang, 2022, American heart journal.

The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).

Frank Litvack, Patrick W Serruys, Eduardo Sousa, 2005, Journal of the American College of Cardiology.

Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.

N. Weissman, K. Kent, A. Pichard, 2004, Journal of the American College of Cardiology.

Effect of Variable Dose and elease Kinetics on Neointimal Hyperplasia sing a Novel Paclitaxel-Eluting Stent Platform he Paclitaxel In-Stent Controlled Elution Study ( PISCES ) atrick

P. Smits, A. Abizaid, G. Sianos, 2016 .

ral Rapamycin to Inhibit Restenosis fter Stenting of De Novo Coronary Lesions he Oral Rapamune to Inhibit Restenosis ( ORBIT ) Study on Waksman , MD , *

N. Weissman, K. Kent, A. Pichard, 2016 .